Sigma-Aldrich® and The Scripps Research Institute Partner to Accelerate the Commercialization of Research Reagents

 Sigma-Aldrich® and The Scripps Research Institute Partner to Accelerate the
                    Commercialization of Research Reagents

Agreement marks first partnership of its kind between a research institution
and reagents company; third major deal in TSRI's new partnering strategy

PR Newswire

SAINT LOUIS and LA JOLLA, Calif., July 18, 2013

SAINT LOUIS and LA JOLLA, Calif., July 18, 2013 /PRNewswire/ --Sigma-Aldrich
Corporation (Nasdaq: SIAL) today announced a partnership with The Scripps
Research Institute (TSRI) to fund research and provide immediate,
day-of-publication access to TSRI researchers' discoveries for the synthesis
and analysis of potential drugs. The partnership promises to eliminate months
from the translation of cutting-edge chemistry into widespread applications
for drug discovery.

The partnership includes six TSRI research labs led by Professors Phil Baran,
Jin-Quan Yu, Benjamin Cravatt, Carlos Barbas, Phillip Dawson, and Nobel
Laureate K. Barry Sharpless. TSRI will receive funds to be used to expand
capacity for basic research.

TSRI approached Sigma-Aldrich to eliminate the delay between the invention of
novel reagents and reliable, widespread access to those reagents for the
translational research community. "The hurdles from bench to clinic, what the
NIH calls the 'valley of death', are proving difficult to surmount, leaving
numbers of potential therapeutic ideas trapped inside university doors. To
clear these hurdles, it's critical to open a myriad of novel technologies,
such as these from TSRI, to the whole translational research community," said
Amanda Halford, Vice President, Academic Research at Sigma-Aldrich.

"This is the third major deal in our new targeted partnership strategy,
following recent agreements with Janssen Pharmaceuticals and Bristol-Myers
Squibb," said Scott Forrest, Vice President of Business Development at TSRI.
"These multi-lab, multi-year alliances fund research and infrastructure in
areas of mutual interest, creating a win-win situation for moving innovations
into the marketplace. We are pleased to partner with the world's leading
reagent company to accelerate the commercialization of new research tools for
the scientific community."

Sigma-Aldrich and TSRI will partner to fund development of novel reagents from
the six TSRI labs, which Sigma-Aldrich will commercialize exclusively via a
master licensing agreement. This will allow unfettered access to new reagents
by chemists and also scientists who do not have a background in chemical
synthesis, which in the past limited their ability to implement novel reagents
in their research.

Last year, TSRI and Sigma-Aldrich established a partnership to produce in bulk
a toolkit of ten novel zinc-based salts discovered in the Baran lab, including
the Baran difluoromethylation reagent that several large pharmaceutical
companies immediately adopted for optimizing lead compounds.

"The partnership with TSRI will enable us to expand our portfolio through new
innovations and product development," said Eric Green, Executive Vice
President and President, Research at Sigma-Aldrich. "We believe this
partnership reinforces our strategy of broadening our research portfolio of
innovative products and tools used by the translational research community."

Publications of new reagents developed in these six TSRI labs will include a
Sigma-Aldrich product number for simple reference.

While a number of collaborative partnerships have emerged between academic
institutions and pharmaceutical companies, this is the first partnership of
its kind between a research institute and a reagents company.

For more information, visit

Cautionary Statement: The foregoing release contains forward-looking
statements that can be identified by terminology such as "promises to," "will
commercialize," "will create," or similar expressions, or by expressed or
implied discussions regarding potential future revenues from products derived
there from. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that the partnership between
Sigma-Aldrich and TSRI will assist the Company to achieve any particular
levels of revenue in the future. In particular, management's expectations
regarding products associated with the partnership between Sigma-Aldrich and
TSRI could be affected by, among other things, unexpected regulatory actions
or delays or government regulation generally; the Company's ability to obtain
or maintain patent or other proprietary intellectual property protection;
competition in general; government, industry and general public pricing
pressures; the impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in its
consolidated balance sheet, and other risks and factors referred to in
Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the information in this press release as of this
date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

About The Scripps Research Institute: The Scripps Research Institute (TSRI) is
one of the world's largest independent, not-for-profit organizations focusing
on research in the biomedical sciences. TSRI is internationally recognized for
its contributions to science and health, including its role in laying the
foundation for new treatments for cancer, rheumatoid arthritis, hemophilia,
and other diseases. An institution that evolved from the Scripps Metabolic
Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute
now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter,
FL, where its renowned scientists—including three Nobel laureates—work toward
their next discoveries. The institute's graduate program, which awards PhD
degrees in biology and chemistry, ranks among the top ten of its kind in the
nation. For more information, see

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

Sigma-Aldrich is a trademark of Sigma-Aldrich Co, LLC registered in the US and
other countries.

SOURCE Sigma-Aldrich Corporation

Contact: Sigma-Aldrich, Jen McMahon, + (1) 314-236-0986,;
or Media Inquiries: Harris D. McKinney, Inc, Alan Zachary, Ph.D., + (1)
312-506-5220,; or The Scripps Research Institute,
Mika Ono, + (1) 858-784-2052,
Press spacebar to pause and continue. Press esc to stop.